Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-1710962 | ...

or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2021 | Common stock, $0.001 par value per | | | | --- | --- | --- | | Title of each class share | Trading Symbo ...

Financial Data and Key Metrics Changes - The company recognized revenue of $3.1 million for Q2 2021, compared to no revenue in Q2 2020, as the acquisition of RareGen was completed in November 2020 [20] - Research and Development expenses decreased to $4.6 million in Q2 2021 from $8.5 million in Q2 2020, a reduction of approximately 46% [21] - General administrative expenses were $4.4 million in Q2 2021, down from $5.2 million in the same quarter of the previous year, a decrease of roughly 15% [22] - The net loss for Q2 2021 was $6.5 million or $0.13 per share, compared to a net loss of $13.9 million or $0.49 per share in Q2 2020 [23] - Cash at the end of Q2 2021 was $67.9 million, an increase from $65.3 million at the end of 2020 [24] Business Line Data and Key Metrics Changes - The launch of the RG 3ml Medication Cartridge for Treprostinil Injection has more than doubled the addressable market for the product [6] - The company has seen positive uptake and patient conversions for the generic Treprostinil Injection since its launch in June 2021 [31] Market Data and Key Metrics Changes - There is strong payer engagement and interest in increasing the utilization of generic Treprostinil, indicating a positive market response [31] Company Strategy and Development Direction - The company aims to optimize Treprostinil Injection sales, achieve tentative approval for LIQ861, and resolve the Hatch-Waxman Litigation to launch LIQ861 in 2022 [26] - The company is treating the commercialization of its generic product similarly to a brand, with a dedicated sales force and a VP of Market Access to work with payers [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver on its objectives and emphasized the importance of financial stability and disciplined spending [5][17] - The company is optimistic about receiving tentative approval for LIQ861 and is prepared for FDA inspections [14] Other Important Information - The FDA has set a PDUFA date of November 7, 2021, for the resubmission of the NDA for LIQ861 [13] - The company is involved in ongoing litigation with United Therapeutics, which is critical for its future product offerings [15][16] Q&A Session Summary Question: What is the split this quarter between IV and subcutaneous generic Treprostinil sales? - The company is not disclosing the split at this time but noted that the launch has gone well with positive uptake and patient conversions [30] Question: Can you provide additional details on the claims construction? - The judges ruled on three terms, with two terms given their plain and ordinary meaning and one term ruled in favor of the company [32] Question: What regulatory steps are needed to achieve approval for ILD indication? - The company intends to pursue the ILD indication after the expiration of United Therapeutics' data exclusivity in March 2024 [34] Question: Is there additional contracting required for patient access to the subcutaneous product? - Currently, all patients have access to the generic Treprostinil without additional contracting [38] Question: Have you reached the profit split threshold with Sandoz? - The threshold has not been met yet, but it is anticipated to be reached by the end of Q3 or beginning of Q4 [39]

( ) Liquidia® DRPORATION == Corporate Overview May 2021 Forward-Looking Statements 2 2 This presentation includes, and our response to various questions may include, forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation other than statements of historical facts, including statements regarding our future resu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-1710962 | | - ...

Liquidia Technologies, Inc. (NASDAQ:LQDA) Q1 2021 Earnings Conference Call May 13, 2021 8:30 AM ET Company Participants Jason Adair - Business Development & Investor Relations Damian deGoa - Chief Executive Officer Michael Kaseta - Chief Financial Officer Conference Call Participants Shveta Dighe - Wedbush Securities Operator Good morning and welcome, everyone, to the Liquidia Corporation First Quarter 2021 Financial Results and Corporate Update Conference Call. My name is Anthony, and I'll be your conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-1710962 | | --- | --- | | (State o ...

Liquidia Technologies, Inc. (NASDAQ:LQDA) Q4 2020 Earnings Conference Call March 23, 2021 8:30 AM ET Company Participants Jason Adair - Business Development & Investor Relations Damian deGoa - Chief Executive Officer Michael Kaseta - Chief Financial Officer Conference Call Participants Chris Howerton - Jefferies Andreas Argyrides - Wedbush Securities Serge Belanger - Needham & Company Operator Good morning and welcome, everyone, to the Liquidia Corporation Full Year 2020 Financial Results and Corporate Upda ...

Liquidia Technologies, Inc. (NASDAQ:LQDA) Q3 2020 Earnings Conference Call November 9, 2020 8:00 AM ET Company Participants Jason Adair - Vice President, Corporate Development and Strategy Neal Fowler - CEO Steve Bariahtaris - Interim CFO Conference Call Participants Serge Belanger - Needham & Company Operator Good morning, ladies and gentlemen. My name is April, and I will be your conference operator today. I would like to welcome everyone to the Liquidia Technologies Third Quarter 2020 Financial Results a ...

LIQUIDIA Corporate Overview August 11, 2020 Forward-Looking Statements 2 This presentation includes, and our response to various questions may include, forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operati ...